JP6574245B2 - 増殖性障害を処置するための組成物および方法 - Google Patents

増殖性障害を処置するための組成物および方法 Download PDF

Info

Publication number
JP6574245B2
JP6574245B2 JP2017512759A JP2017512759A JP6574245B2 JP 6574245 B2 JP6574245 B2 JP 6574245B2 JP 2017512759 A JP2017512759 A JP 2017512759A JP 2017512759 A JP2017512759 A JP 2017512759A JP 6574245 B2 JP6574245 B2 JP 6574245B2
Authority
JP
Japan
Prior art keywords
cancer
pharmaceutical composition
cells
cell
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017512759A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017526698A5 (cg-RX-API-DMAC7.html
JP2017526698A (ja
Inventor
ダニエル ティー. ドランスフィールド
ダニエル ティー. ドランスフィールド
サダーシャン イーシラジ
サダーシャン イーシラジ
ジャン−マルク ラピエール
ジャン−マルク ラピエール
ブライアン シュワルツ
ブライアン シュワルツ
イ ユ
イ ユ
Original Assignee
アークル インコーポレイテッド
アークル インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アークル インコーポレイテッド, アークル インコーポレイテッド filed Critical アークル インコーポレイテッド
Publication of JP2017526698A publication Critical patent/JP2017526698A/ja
Publication of JP2017526698A5 publication Critical patent/JP2017526698A5/ja
Application granted granted Critical
Publication of JP6574245B2 publication Critical patent/JP6574245B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Epoxy Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
JP2017512759A 2014-09-05 2015-09-04 増殖性障害を処置するための組成物および方法 Expired - Fee Related JP6574245B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462046502P 2014-09-05 2014-09-05
US62/046,502 2014-09-05
US201462082236P 2014-11-20 2014-11-20
US62/082,236 2014-11-20
PCT/US2015/048520 WO2016037044A1 (en) 2014-09-05 2015-09-04 Compositions and methods for treating proliferation disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019149011A Division JP6837525B2 (ja) 2014-09-05 2019-08-15 増殖性障害を処置するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2017526698A JP2017526698A (ja) 2017-09-14
JP2017526698A5 JP2017526698A5 (cg-RX-API-DMAC7.html) 2018-10-04
JP6574245B2 true JP6574245B2 (ja) 2019-09-11

Family

ID=55436479

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017512759A Expired - Fee Related JP6574245B2 (ja) 2014-09-05 2015-09-04 増殖性障害を処置するための組成物および方法
JP2019149011A Expired - Fee Related JP6837525B2 (ja) 2014-09-05 2019-08-15 増殖性障害を処置するための組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019149011A Expired - Fee Related JP6837525B2 (ja) 2014-09-05 2019-08-15 増殖性障害を処置するための組成物および方法

Country Status (14)

Country Link
US (1) US9949981B2 (cg-RX-API-DMAC7.html)
EP (1) EP3189036B1 (cg-RX-API-DMAC7.html)
JP (2) JP6574245B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170045748A (cg-RX-API-DMAC7.html)
CN (2) CN107074769B (cg-RX-API-DMAC7.html)
AU (2) AU2015311751B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017004459A2 (cg-RX-API-DMAC7.html)
CA (1) CA2958770A1 (cg-RX-API-DMAC7.html)
ES (1) ES2955926T3 (cg-RX-API-DMAC7.html)
IL (2) IL250715B (cg-RX-API-DMAC7.html)
MX (1) MX382891B (cg-RX-API-DMAC7.html)
RU (2) RU2711500C2 (cg-RX-API-DMAC7.html)
SG (1) SG11201701704XA (cg-RX-API-DMAC7.html)
WO (1) WO2016037044A1 (cg-RX-API-DMAC7.html)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20190105669A (ko) 2012-10-15 2019-09-17 에피자임, 인코포레이티드 암을 치료하는 방법
WO2017035234A1 (en) 2015-08-24 2017-03-02 Epizyme, Inc. Method for treating cancer
EP3430405B1 (en) * 2016-03-14 2023-08-09 Pierce Biotechnology Inc. Detection and quantification of akt-mtor pathway proteins
US11352328B2 (en) 2016-07-12 2022-06-07 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus
CN110366413A (zh) * 2017-02-02 2019-10-22 Epizyme股份有限公司 癌症治疗形式
WO2019071171A1 (en) * 2017-10-05 2019-04-11 The Board Of Trustees Of The University Of Illinois Method of treating sickle cell disease
CN110669015A (zh) * 2018-07-03 2020-01-10 上海喀露蓝科技有限公司 一种fgfr抑制剂的制备方法
EP3880202A2 (en) * 2018-11-16 2021-09-22 ArQule, Inc. Pharmaceutical combination for treatment of cancer
US12419865B2 (en) 2018-12-06 2025-09-23 Arisan Therapeutics Inc. Compounds for the treatment of arenavirus infection
US12617784B2 (en) 2019-01-29 2026-05-05 Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. AKT inhibitor
WO2020181009A1 (en) * 2019-03-04 2020-09-10 Northwestern University Bacterial enzymatic conversion of anthracyclie chemotherapeutics
WO2022053708A1 (en) * 2020-09-14 2022-03-17 Basilea Pharmaceutica International AG Pharmaceutical combinations for use in the treatment of gastric adenocarcinoma
AU2021351093A1 (en) * 2020-09-30 2023-06-01 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Compound as akt kinase inhibitor
CN112225745B (zh) * 2020-11-16 2021-10-12 烟台大学 一种具有抗肿瘤活性的异片螺素类化合物、制备方法及用途
WO2023168291A1 (en) * 2022-03-02 2023-09-07 Terremoto Biosciences, Inc. Covalent modifiers of akt1 and uses thereof
KR20260065819A (ko) 2023-08-04 2026-05-11 테레모토 바이오사이언스, 인코포레이티드 AKT1의 비공유결합 변형제로서의 3H-이미다조[4,5-b]피리딘 화합물 및 이의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201036614A (en) * 2008-12-30 2010-10-16 Arqule Inc Substituted 1H-pyrazolo[3,4-d]pyrimidine-6-amine compounds
CN102325755B (zh) * 2008-12-30 2015-07-01 艾科尔公司 取代的5,6-二氢-6-苯基苯并[f]异喹啉-2-胺化合物
US8049005B2 (en) * 2009-03-31 2011-11-01 Arqule, Inc. Substituted tetrahydropyrazolo-pyrido-azepine compounds
CA2785536C (en) * 2009-12-30 2018-02-27 Arqule, Inc. Substituted imidazopyridinyl-aminopyridine compounds
WO2012177852A1 (en) * 2011-06-24 2012-12-27 Arqule, Inc Substituted imidazopyridinyl compounds
DK2723741T3 (en) 2011-06-24 2016-06-06 Arqule Inc SUBSTITUTED imidazopyridinyl-aminopyridine compounds

Also Published As

Publication number Publication date
RU2017111204A (ru) 2018-10-05
JP6837525B2 (ja) 2021-03-03
WO2016037044A1 (en) 2016-03-10
EP3189036A4 (en) 2018-04-04
RU2711500C2 (ru) 2020-01-17
US20160067260A1 (en) 2016-03-10
KR20170045748A (ko) 2017-04-27
MX382891B (es) 2025-03-13
RU2017111204A3 (cg-RX-API-DMAC7.html) 2019-03-25
AU2020203706B2 (en) 2022-01-13
BR112017004459A2 (pt) 2017-12-05
CA2958770A1 (en) 2016-03-10
MX2017002892A (es) 2017-06-06
CN111494378A (zh) 2020-08-07
ES2955926T3 (es) 2023-12-11
RU2019142694A (ru) 2020-02-26
EP3189036A1 (en) 2017-07-12
AU2015311751A1 (en) 2017-03-09
IL250715B (en) 2020-09-30
IL277028A (en) 2020-10-29
EP3189036B1 (en) 2023-07-19
CN107074769B (zh) 2020-04-07
AU2020203706A1 (en) 2020-06-25
AU2015311751B2 (en) 2020-03-12
IL250715A0 (en) 2017-04-30
CN107074769A (zh) 2017-08-18
US9949981B2 (en) 2018-04-24
JP2017526698A (ja) 2017-09-14
SG11201701704XA (en) 2017-04-27
JP2020002148A (ja) 2020-01-09

Similar Documents

Publication Publication Date Title
JP6837525B2 (ja) 増殖性障害を処置するための組成物および方法
JP6046710B2 (ja) 置換されたイミダゾピリジニル−アミノピリジン化合物
JP5774602B2 (ja) 置換されたイミダゾピリジニル−アミノピリジン化合物
US8497276B2 (en) Substituted indolo-piperidine compounds
US8563567B2 (en) Substituted heterocyclic compounds
US8815854B2 (en) Substituted imidazopyridinyl compounds
US8541407B2 (en) Substituted benzo-pyrido-triazolo-diazepine compounds
JP2013516420A (ja) 置換されたピロロ−アミノピリミジン化合物
JP2017190337A (ja) がんを処置するための組合せ治療
WO2014164729A1 (en) Substituted tricyclic pyrazolo-pyrimidine compounds
JP5984837B2 (ja) ピロロキノリニル−ピロリジン−2,5−ジオン組成物ならびにそれを調製および使用する方法
US8049005B2 (en) Substituted tetrahydropyrazolo-pyrido-azepine compounds
US8906928B2 (en) Substituted pyrazolo-pyrrolo-pyridine-dione compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180824

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180824

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190717

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190815

R150 Certificate of patent or registration of utility model

Ref document number: 6574245

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees